Tell us about Lindus Health
Lindus Health is a London-based start-up that runs clinical trials three times faster than the old-fashioned industry standard – bringing ground-breaking treatments to patients sooner.
Clinical trials are the biggest bottleneck to advances in healthcare and by removing this constraint we aim to improve health for everyone.
We do this through our technology platform that enables us to deliver faster, more reliable clinical trials from start to finish. From monitoring trial data in real time to using machine learning to predict outcomes and make improvements to trial designs in advance, we are simplifying the clinical trials process and putting patients first.
We’ve delivered trials across the UK, US and Europe to tackle a range of conditions including diabetes, asthma, acne, major depressive disorder, hypertension, social anxiety and insomnia.
What do you think makes this company unique?
The scope of what we can offer to companies running clinical trials, by handling all aspects of trial design, recruitment and delivery from start to finish, is what sets Lindus Health apart.
We are the only industry provider with a fully integrated clinical trial system that underpins all our clinical operations. We take the guesswork out of trial design by using machine learning models to predict likely trial outcomes and suggest improvements in advance. We also use machine learning algorithms to spot, prevent, and correct flawed data, and to predict and intervene when participants are at risk of dropping out.
Our technology also monitors data in real time – tracking progress from recruitment to results and minimising the need for time-consuming and expensive manual monitoring – and every trial is designed with the patient at its heart, helping to improve patients’ experiences and ultimately leading to better quality data.
The traditional Contract Research Organisations that have previously run clinical trials are dinosaurs, outsourcing almost all aspects of trial delivery. This has led to the UK lagging behind globally – with 86% of clinical trials delayed and fewer Phase III trials than countries including Spain, France, Germany, Poland and Italy.
Lindus Health was founded to transform the clinical trials space and bring it into the 21st century.
Combining unique perspectives, we aimed to use technology to run faster, more reliable clinical trials and cut through the stifling levels of bureaucracy to make real progress in drug development.
More from Interviews
- A Chat With Oluwasesan Kayode Yackson, Co-Founder And COO at ProtonLabs Technology Inc. Ltd. and TechRound SaaS66 2026 Judge
- A Chat With Abiel Ghezae, Founder And CEO Of Ahlan, On Building The Operating System For Global Mobility
- A Chat With Cathie Hall, Chief Customer And Product Officer At IFS, On How AI Can Preserve Institutional Knowledge
- A Chat With Dr Kayode Adedapo Kolawole, Sales Director At Nagode Industries And SaaS 66 Judge
- A Chat With Dearbhail Ormond, Founder Of frendo, On Building Free Support For Endometriosis
- A Conversation With Semrush On AI Search, Brand Visibility And Spotlight 2026
- A Chat With Ollie Whiting, CEO Of La Fosse, On The Human Side Of Digital Change
- A Chat With Chris Kincade, Founder Of Starling Memory Works, On Why Your AI Doesn’t Know Your Business
What has the company accomplished over the last couple of years?
Since launching in 2021, we have delivered more than 80 trials across the UK, US and Europe to tackle a range of conditions including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. To date, 20,000 people have taken part in our clinical trials.
Our partners have included the University of Oxford, the University of Cambridge, Yale University, Imperial College London and AstraZeneca, as well as exciting start-ups pioneering new drugs and treatments.
100% of our clinical trials are completed on or ahead of schedule – and three times faster than our competitors.
What can we hope to see from Lindus Health in the future?
Our work so far to bring much needed change to the clinical trials industry is just the start.
We’re looking to grow our operations in the UK, US and Europe in order to provide the benefits of our unique fully integrated clinical trial system to drug developers in as many disease areas as possible. In the long term, this could lead to bringing pioneering new drugs to market sooner, and cheaper, than would otherwise be possible.
On the trial side, we’re currently running trials across a range of therapeutic areas, including myasthenia gravis, asthma, acne and Type 2 diabetes. We’re also kicking off ground-breaking trials this summer for treatments for conditions including tinnitus, severe insomnia, and childhood short-sightedness.
